WEDNESDAY, Aug. 4 (HealthDay News) -- In type 2 diabetes patients, treatment with a glucagon-like peptide (GLP-1) receptor agonist is associated with weight loss and an improved cardiovascular risk profile, according to research published in the August issue of Diabetes Care.
